nach oben

Supportive Care in Cancer

Erschienen in:

01.02.2016 | Original Article

Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

verfasst von: E. Gustafsson, E. Litström, C. Berterö, J. Drott

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to test the reliability of the Swedish version of the Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ) administrated throughout a self-reported mobile phone-based system, a pilot study.

Methods

Twenty-three patients from two university hospitals and two regional hospitals who had been treated with oxaliplatin were included through purposive sampling between autumn 2013 to autumn 2014. A test-retest was performed through a mobile phone-based system, with a recall period of 1 h to determine the reliability of the questionnaire.

Results

Internal consistency was strong for the three domains of the scale (α > 0.840). The statistical analyses for the test-retest indicated that the OANQ was stable. Intraclass correlation (ICC) for symptom items and effect on daily activities items showed an overall excellent reproducibility at 69 and 83 %, respectively. The weighted kappa for symptom items and daily activities items showed an overall almost perfect agreement at 59 and 52 %, respectively. A paired samples t test did not reveal any significant differences between the two measures.

Conclusions

The OANQ was tested and considered a reliable assessment for capturing the oxaliplatin-induced peripheral neurotoxicity (OIPN) in patients receiving oxaliplatin. However, further reliability testing of the OANQ is needed.

Grenon N, Chan J (2009) Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses. Clin J Oncol Nurs 13(3):285–296. doi:10.1188/09.CJON.285-296 PubMedCrossRef

Velasco R, Bruna J, Briani C et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Pschiatry 85(4):392–398. doi:10.1136/jnnp-2013-305334 CrossRef

André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116. doi:10.1200/JCO.2008.20.6771 PubMedCrossRef

Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21(12):3307–3313. doi:10.1007/s00520-013-1905-5 PubMedCrossRef

Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205–2211PubMedCrossRef

Tofthagen C, McAllister RD, McMillan SC (2011) Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs 15(2):182–188. doi:10.1188/11.CJON.182-188 PubMedCrossRef

Park BS, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437. doi:10.3322/caac.21204 PubMedCrossRef

Kidwell K, Yothers G, Ganz P et al (2012) Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer. Cancer 118(22):5614–5622. doi:10.1002/cncr.27593 PubMedPubMedCentralCrossRef

Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13–16PubMedCrossRef

10.

Vatandoust A, Joshi R, Pittman KB et al (2014) A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer 22(2):513–518PubMedCrossRef

11.

Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C et al (2014) Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol 89(1):166–178. doi:10.1016/j.critrevonc.2013.08.009 PubMedCrossRef

12.

Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507–1515. doi:10.1016/j.ejca.2008.04.018 PubMedCrossRef

13.

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. doi:10.1200/JCO.2013.54.0914 PubMedCrossRef

14.

Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367PubMedPubMedCentralCrossRef

15.

Larsen ME, Rowntree J, Young AM et al (2008) Chemotherapy side-effect management using mobile phones. Conf Proc IEEE Eng Med Biol Soc 2008:5152–5155. doi:10.1109/IEMBS.2008.4650374 PubMed

16.

McCann L, Maguire R, Miller M, Kearney N (2009) Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care 18(2):156–164. doi:10.1111/j.1365-2354.2008.00938.x CrossRef

17.

Mirkovic J, Kaufman DR, Ruland CM (2014) Supporting cancer patients in illness management: usability evaluation of a mobile app. JMIR Mhealth Uhealth 2(3):e33. doi:10.2196/mhealth.3359 PubMedPubMedCentralCrossRef

18.

Maguire R, McCann L, Miller M, Kearney N (2008) Nurses’ perceptions and experiences of using of a mobile-phone-based advanced symptom management system (AsyMS©) to monitor and manage chemotherapy-related toxicity. Eur J Oncol Nurs 12(4):380–386. doi:10.1016/j.ejon.2008.04.007 PubMedCrossRef

19.

Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479–494. doi:10.1016/j.ejca.2009.12.008 PubMedCrossRef

20.

Kopec JA, Land SR, Cecchini RS et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4(8):W1–W8

21.

Leonard GD, Wright MA, Quinn MG et al (2005) Survey of oxaliplatin-associated neurotoxicity using and interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 16(5):16. doi:10.1186/1471-2407-5-116

22.

Driessen CML, Kleine-Bolt KME, Vingerhoets AJJM, Mols F, Vreugdenhil G (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881. doi:10.1007/s00520-011-1336-0 PubMedPubMedCentralCrossRef

23.

Cathomas R, Köberle D, Ruhstaller T et al (2010) Heated (37 °C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 18(10):1263–1270. doi:10.1007/s00520-009-0740-1 PubMedCrossRef

24.

Drott JE, Starkhammar H, Börjesson S, Berterö C (2014) Oxaliplatin induced neurotoxicity among patients with colorectal cancer: documentation in medical records—a pilot study. Open J Nurs 4:265–274. doi:10.4236/ojn.2014.44031 CrossRef

25.

Brislin RW (1970) Back-translation for cross-cultural research. J Cross-Cult Psychol 1(3):185–216. doi:10.1177/135910457000100301 CrossRef

26.

Acquadro C, Conway K, Giroudet C, Mear I (2012) Linguistic validation manual for health outcome assessments. MAPI Institute, Lyon

27.

Mokkink LB, Terweea CB, Patrick DL et al (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 63(7):737–745. doi:10.1016/j.jclinepi.2010.02.006 PubMedCrossRef

28.

Rosner B (2011) Fundamentals of biostatistics. Brooks, Boston

29.

Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360–363PubMed

30.

Polit DF (2014) Getting serious about test-retest reliability: a critique of retest research and some recommendations. Qual Life Res 23(6):1713–1720. doi:10.1007/s11136-014-0632-9 PubMedCrossRef

31.

Field A (2013) Discovering statistics using IBM SPSS statistics: and sex and drugs and rock ‘n’ roll, 4th edn. Sage, Los Angeles

32.

Polit DF, Beck CT (2012) Nursing research, generating and assessing evidence for nursing practice, 9th edn. Lippincott Williams & Wilkins, Philadelphia

33.

Berger A, Edwards Neumark D, Chamberlain J (2007) Enhancing recruitment and retention in randomized controlled clinical trials of cancer symptom management. Oncol Nurs Forum 34(2):e17–e22PubMedCrossRef

34.

Ganz PA, Land SR, Antonio C et al (2009) Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv 3(3):137–147. doi:10.1007/s11764-009-0093-2 PubMedPubMedCentralCrossRef

35.

Paul C, Courtney R, Sanson-Fisher R et al (2014) A randomized controlled trial of the effectiveness of a pre-recruitment primer letter to increase participation in a study of colorectal screening and surveillance. BMC Med Res Methodol. 14:44 http://biomedcentral.com/1471-2288/14/44

36.

Hobart JC, Cano SJ, Warner TT, Thompson AJ (2012) What sample sizes for reliability and validity studies in neurology? J Neurol 259(12):2681–2694. doi:10.1007/s00415-012-6570-y PubMedCrossRef

37.

Stull DE, Kline Leidy N, Parasuraman B, Chassany O (2009) Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 25(4):929–942. doi:10.1185/03007990902774765 PubMedCrossRef

38.

Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. doi:10.1016/j.pain.2014.09.020 PubMedCrossRef

39.

Bakitas M (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331PubMedCrossRef

40.

Bennett BK, Park SB, Lin CSY, Friedlander ML, Kiernan MC, Goldstein D (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20(11):2959–2967PubMedCrossRef

41.

Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999–2007. doi:10.1007/s00520-014-2242-z PubMedCrossRef

42.

Velikova G, Keding A, Harley C et al (2010) Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomized controlled trial. Eur J Cancer 46(13):2381–2388. doi:10.1016/j.ejca.2010.04.030 PubMedCrossRef

43.

Dickinson R, Hall S, Sinclair JE, Bond C, Murchie P (2014) Using technology to deliver cancer follow-up: a systematic review. BMC Cancer 14:(1)311 http://biomedcentral.com/1471-2407/14/311

44.

Børøsund E, Ruland CM, Moore S, Ekstedt M (2014) Nurses’ experiences of using an interactive tailored patient assessment tool one year past implementation. Int J Med Inform 83(7):e23–e34. doi:10.1016/j.ijmedinf.2013.10.010 PubMedCrossRef

Titel: Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study
verfasst von: E. Gustafsson
E. Litström
C. Berterö
J. Drott
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 2/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2838-y

Springer Medizin

Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Comparison of subgroups of breast cancer patients on pain and co-occurring symptoms following chemotherapy

Correlates of physical activity among colorectal cancer survivors: results from the longitudinal population-based profiles registry

Preventive effects of amino-acid-rich elemental diet Elental® on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study

The assessment of anorexia in patients with cancer: cut-off values for the FAACT–A/CS and the VAS for appetite

Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

Improving psychosocial outcomes for caregivers of people with poor prognosis gastrointestinal cancers: a randomized controlled trial (Family Connect)

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie